Targeted therapies available for the treatment of cancer are increasingly being considered as standards of care in routine clinical practice. These therapies, such as Crizotinib for non-small cell lung cancer and Cextuximab for colorectal cancer are recommended for single tumour types. However, third generation therapies targeting fusion genes have received licensing approval and are being read more…